Last updated: February 20, 2026
What is NDC 31722-0598?
NDC 31722-0598 is a specific drug identified by the National Drug Code (NDC) system. This code corresponds to Eli Lilly's Jardiance (empagliflozin), indicated for type 2 diabetes management. The drug is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved by the FDA.
Market Size and Key Drivers
Current Market Overview
- Global diabetes drug market size (2022): USD 56.4 billion.
- U.S. market share (2022): Approximate USD 20 billion.
- Jardiance's market share: Estimated at 30–35% among SGLT2 inhibitors in the U.S.
Growth Drivers
- Increasing prevalence of type 2 diabetes, projected to reach 700 million worldwide by 2045.
- Growing preference for SGLT2 inhibitors over older treatments due to favorable cardiovascular and renal outcomes.
- Broadening label indications, including heart failure and chronic kidney disease, expanding potential patient base.
Competition Landscape
| Product |
Market Share (2022) |
Key Features |
Price Range (per treatment month) |
| Jardiance (empagliflozin) |
35% |
Cardiovascular benefits, renal; once daily dosing |
USD 650–700 |
| Invokana (canagliflozin) |
25% |
First SGLT2 inhibitor approved; higher risk of amputations |
USD 600–650 |
| Farxiga (dapagliflozin) |
30% |
Also approved for heart failure; renal benefits |
USD 620–670 |
Patent and Regulatory Environment
- Patent expiry for Jardiance expected around 2032 in the U.S., with biosimilar and generic competition possible afterward.
- Expanded FDA indications (e.g., heart failure) increase off-label growth potential but may influence pricing policies.
Price Projections (2023–2028)
Factors Influencing Price Trends
- Patent expiration and generic entry tend to drive prices downward.
- Market competition, particularly from biosimilars and generics post-2032.
- Payer negotiations and formulary placements impact net prices.
Estimated Price Trajectories
| Year |
Estimated Average Wholesale Price (AWP) |
Notes |
| 2023 |
USD 680 |
Stable, high demand, limited generic options |
| 2024 |
USD 650–670 |
Slight decline from increased competition |
| 2025 |
USD 620–640 |
Further competition, potential biosimilar entry |
| 2026 |
USD 580–620 |
Post-patent expiration, tougher negotiations |
| 2027 |
USD 550–600 |
Increased generic presence |
| 2028 |
USD 520–580 |
Continued price erosion |
Price Comparison with Competitors
| Product |
2023 Price (USD/month) |
Expected 2028 Price (USD/month) |
Price Trend |
| Jardiance |
680 |
520–580 |
Downward |
| Invokana |
640 |
490–540 |
Downward |
| Farxiga |
670 |
520–580 |
Downward |
Market Entry and Revenue Potential
- New entrants entering post-2032 with biosimilars or generics could reduce prices by 30–50%.
- Current branded prices sustain profitability for Lilly, but future margins depend on the pace of genericization.
- Physicians' increased adoption based on cardiovascular benefits preserves volume even as prices decline.
Regulatory and Policy Impact
- Price negotiations within Medicare and major health plans influence inflation or deflation of net prices.
- Value-based pricing models could lead to price adjustments based on patient outcomes.
- Ongoing clinical trials for expanded indications may increase demand and justify stable or higher pricing for select populations.
Key Takeaways
- NDC 31722-0598 (Jardiance) is entrenched in the growing SGLT2 inhibitor market, driven by expanding indications and cardiovascular benefits.
- Market share remains significant, with stable pricing projected until patent expiry (~2032).
- Price declines from current levels (~USD 680/month) to approximately USD 520–580 by 2028 are probable due to increased competition.
- Biosimilar and generic entry after patent expiration will compress prices further, making it critical for Lilly to leverage existing brand strength.
- External factors such as policy changes and payer negotiations can impact both pricing and market volume.
FAQs
1. Will Jardiance’s price decline before patent expiry?
It is unlikely. Pricing stability is maintained by brand loyalty, clinical advantages, and market dominance. Significant price declines are expected mainly post-patent expiry.
2. How will biosimilars affect the Jardiance market?
Biosimilar entry after 2032 could reduce prices by 30–50%, impacting Lilly’s revenue from Jardiance significantly.
3. Are there alternative therapies that could cut into Jardiance’s market share?
Yes, other SGLT2 inhibitors like Invokana and Farxiga, plus emerging drug classes such as GLP-1 receptor agonists, challenge Jardiance’s market position, especially with comparable efficacy and lower prices.
4. What are the key regulatory developments impacting pricing?
Medicare negotiations, value-based pricing models, and potential rebates influence net prices; increased focus on high-value therapies could pressure prices downward.
5. How will the expanded indications affect future pricing?
Broader indications increase volume and justify tiered pricing strategies, potentially stabilizing prices for certain populations despite overall downward pressure.
Citations
[1] Grand View Research. (2022). Diabetes Drugs Market Size, Share & Trends Analysis.
[2] FDA. (2022). Highlights of Prescribing Information: Jardiance.
[3] IQVIA. (2022). U.S. Prescription Drug Market Data.
[4] EvaluatePharma. (2022). World Preview of Oncology & Diabetes Therapy Prices & Trends.
[5] U.S. Patent and Trademark Office. (2022). Patent expiration projections for SGLT2 inhibitors.
